REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

sarilumab

Effective Date: March 2022 **Revised Date:**	CLASSIFICATION **Monoclonal Antibody**	OTHER NAMES Kevzara	PAGE 1 of 1

ADMINISTRATION POLICY:

IV Intermittent - May be administered by a nurse
IV Bolus - *DO NOT give*
IM Injection - *DO NOT give*
Subcutaneous - May be administered by a nurse

RECONSTITUTION/DILUTION/ADMINISTRATION:

Supplied as 200 mg/1.14 mL syringe. Keep in refrigerator

IV Intermittent -
- Using Subcut formulation,
- Leave syringe to sit at room temperature for 30 minutes
- Solution should be clear and colorless to pale yellow
- Do not shake
- Dilute in 100 mL normal saline and administer over 1 hour

DOSAGE:

Usual:	400 mg IV x 1
Maximum single dose:	400 mg
Maximum daily dose:	400 mg

STABILITY/COMPATIBILITY:

Stability of Final Admixture:	Maximum 6 hours at room temperature Maximum 24 hours refrigerated
Compatibility:	Compatible with NaCl 0.9%

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Gastrointestinal: perforation
- Infection: serious and potentially fatal infections (including active tuberculosis, invasive fungal, bacterial, viral and other opportunistic infections) have been reported. Most of the serious infections have occurred in patients on concomitant immunosuppressive therapy.
- Hypersensitivity reactions: injection-site rash, rash and urticaria.
- Anaphylaxis

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Healthcare provider must have the ability to respond to infusion reactions.
- Use in combination with glucocorticoids
- Avoid use in combination with baricitinib or tofacitinib
- **Required monitoring** for infusion-related reactions and hypersensitivity/anaphylaxis during infusion and for 1 hour following infusion completion.
- Closely monitor for signs/symptoms of infection during treatment.
- If infusion-related reaction occurs, temporarily or permanently discontinue infusion (depending on the severity of the reaction and required interventions).
- Postpone vaccination for at least 90 days after receipt of monoclonal antibody products used for the treatment of COVID-19. Postpone vaccination for at least 30 days after receipt of monoclonal antibodies used for post-exposure prophylaxis.